The monoclonal antibodies panitumumab and cetuximab that target the epidermal growth
factor receptor (EGFR) have expanded the range of treatment options for metastatic …

The tropomyosin receptor kinase (Trk) receptor family comprises 3 transmembrane proteins
referred to as Trk A, B and C (TrkA, TrkB and TrkC) receptors that are encoded by the …

Treatment of young adults with colorectal cancer (CRC) represents an unmet clinical need,
especially as diagnosis in this population might lead to the greatest loss of years of life …

A main limitation of therapies that selectively target kinase signalling pathways is the
emergence of secondary drug resistance. Cetuximab, a monoclonal antibody that binds the …

The development of noninvasive methods to detect and monitor tumors continues to be a
major challenge in oncology. We used digital polymerase chain reaction–based …

Background Following the discovery that mutant KRAS is associated with resistance to anti-
epidermal growth factor receptor (EGFR) antibodies, the tumours of patients with metastatic …

Purpose Cetuximab or panitumumab are effective in 10% to 20% unselected metastatic
colorectal cancer (CRC) patients. KRAS mutations account for approximately 30% to 40 …

Only a fraction of patients with metastatic colorectal cancer receive clinical benefit from
therapy with anti-epidermal growth factor receptor (EGFR) antibodies, which calls for the …

Colorectal cancers (CRCs) evolve by a reiterative process of genetic diversification and
clonal evolution. The molecular profile of CRC is routinely assessed in surgical or bioptic …

Background We previously found that dual HER2 blockade with trastuzumab and lapatinib
led to inhibition of tumour growth in patient-derived xenografts of HER2-amplified metastatic …